Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
Maddalena NapolitanoAdriana Di GuidaGabriella FabbrociniCataldo PatrunoPublished in: Dermatologic therapy (2021)
Ocular comorbidities are more frequent in patients with severe atopic dermatitis (AD) compared to general population. Dupilumab, a fully human monoclonal antibody that prevents the signaling of interleukin (IL)-4 and IL-13, is reported to be efficacious and safe for the treatment of moderate-to-severe AD, asthma, and chronic sinusitis. However, conjunctivitis was the most common side effect observed both in clinical trials and real-life studies in atopic patients. In our experience, among all patients treated with dupilumab from June 2018 to February 2021, we observed a total of 42 cases (10.42%) of conjunctivitis, appearing approximately 13.8 weeks after initiating treatment. Thirty-five patients (8.68%) developed mild-to-moderate conjunctivitis, and 7 (1.74%) severe conjunctivitis. The drug was discontinued in all 7 patients with severe conjunctivitis.
Keyphrases
- atopic dermatitis
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- early onset
- monoclonal antibody
- endothelial cells
- prognostic factors
- drug induced
- combination therapy
- randomized controlled trial
- cystic fibrosis
- lung function
- replacement therapy
- open label
- electronic health record
- study protocol
- smoking cessation
- phase ii
- optical coherence tomography